ciprofloxacin has been researched along with Paratyphoid Fever in 39 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Paratyphoid Fever: A prolonged febrile illness commonly caused by several Paratyphi serotypes of SALMONELLA ENTERICA. It is similar to TYPHOID FEVER but less severe.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of two regimens of ciprofloxacin was compared in a randomized study conducted on 69 patients with enteric fever, 52." | 9.08 | Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. ( Alam, MN; Baral, PK; Das, KK; Dutta, P; Haq, SA; Hasan, Z; Khan, MA; Mazid, MN; Rahman, KM; Siddique, RU, 1995) |
| "This report describes a relapse of Salmonella paratyphi B infection in a child with biliary atresia, following 2 weeks of treatment with ciprofloxacin." | 7.69 | A relapse of paratyphoid fever after treatment with ciprofloxacin in a child with congenital biliary atresia. ( Eltringham, IJ; Ireland, D; Irish, D; Issler, H; Teall, A; Thalange, N, 1997) |
| "Two developed recurrence of paratyphoid fever, 17 days and 4 months after therapy." | 6.67 | Short course ciprofloxacin therapy for enteric fever. ( Jesudason, MV; John, J; Kaur, A; Keystone, JS; Kozarsky, PE; Kudva, GC; Lalitha, MK; Mathai, D; Pulimood, BM; Thomas, M, 1993) |
| "The efficacy of two regimens of ciprofloxacin was compared in a randomized study conducted on 69 patients with enteric fever, 52." | 5.08 | Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. ( Alam, MN; Baral, PK; Das, KK; Dutta, P; Haq, SA; Hasan, Z; Khan, MA; Mazid, MN; Rahman, KM; Siddique, RU, 1995) |
| "We report a case of recurrent, multifocal Salmonella enterica serotype Paratyphi A breast abscesses, resistant to ciprofloxacin, which relapsed despite surgery, aspiration and multiple courses of antibiotics, including co-trimoxazole and azithromycin." | 3.78 | Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused by Salmonella enterica serotype Paratyphi A. ( Fernando, S; Gottlieb, T; Molland, JG, 2012) |
| "This report describes a relapse of Salmonella paratyphi B infection in a child with biliary atresia, following 2 weeks of treatment with ciprofloxacin." | 3.69 | A relapse of paratyphoid fever after treatment with ciprofloxacin in a child with congenital biliary atresia. ( Eltringham, IJ; Ireland, D; Irish, D; Issler, H; Teall, A; Thalange, N, 1997) |
| "Thirty adult patients with typhoid or paratyphoid fever were treated with ciprofloxacin." | 3.67 | Open study of ciprofloxacin in enteric fever. ( Flegg, PJ; Geddes, AM; Mandal, BK; Stanley, PJ, 1989) |
| " In an era of increasing antimicrobial resistance, further studies are required to define appropriate azithromycin dosing regimens for enteric fever and to assess novel treatment strategies, including combination therapies." | 2.90 | Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. ( Aljayyoussi, G; Angus, B; Ardrey, A; Biagini, GA; Feasey, NA; Gibani, MM; Jin, C; Liu, X; Moore, M; Parry, CM; Pennington, SH; Pollard, AJ, 2019) |
| "Typhoid and paratyphoid (enteric fever) are febrile bacterial illnesses common in many low- and middle-income countries." | 2.82 | Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. ( Basnyat, B; Darton, TC; Eyre, D; Kuehn, R; Parry, CM; Stoesser, N, 2022) |
| "Assessment of paratyphoid vaccine efficacy in preclinical studies is complicated by the lack of a small animal model and the human-restricted nature of the infection." | 2.80 | Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. ( Angus, B; Campbell, D; Darton, T; Dobinson, HC; Jones, C; Kerridge, S; Martin, LB; McCullagh, D; Plested, E; Pollard, AJ; Snape, M; Stevens, Z; Voysey, M, 2015) |
| "Two developed recurrence of paratyphoid fever, 17 days and 4 months after therapy." | 2.67 | Short course ciprofloxacin therapy for enteric fever. ( Jesudason, MV; John, J; Kaur, A; Keystone, JS; Kozarsky, PE; Kudva, GC; Lalitha, MK; Mathai, D; Pulimood, BM; Thomas, M, 1993) |
| "Despite its excellent antimicrobial activity against salmonellae and its favorable pharmacokinetic profile, ciprofloxacin at a dosage of 750 mg orally twice daily had an unacceptably high failure rate in patients with acute salmonellosis and may have prolonged fecal excretion of salmonellae." | 2.67 | Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. ( Cassidy, JE; Giusti, R; Heelan, J; Mayer, KH; Neill, MA; Opal, SM; White, R, 1991) |
| "We retrospectively reviewed typhoid and paratyphoid fever cases in two medical centers of Chang Gung Memorial Hospitals in 2010-2020." | 1.72 | Clinical manifestations and microbiological features between indigenous and imported enteric fever in Taiwan, 2010-2020. ( Chen, CH; Chen, YC; Cheng, SS; Chiu, CH; Hsu, YJ; Kuo, KC, 2022) |
| "Paratyphoid fever is an acute infection caused by Salmonella paratyphi A, B or C." | 1.35 | [A case of Salmonella paratyphi A infection in Poland]. ( Biesiada, G; Czepiel, J; Garlicki, A; Mach, T; Salamon, D; Skwara, P; Sobczyk-Krupiarz, I, 2008) |
| "We report a case of fulminant hepatic failure associated with Salmonella paratyphi A infection, in a 29-year-old patient who was admitted to the intensive care unit (ICU) with fever of two days, headache and vomiting followed by behavioural changes and disorientation." | 1.33 | Fulminant hepatic failure caused by Salmonella paratyphi A infection. ( Alomary, IY; Kamha, AA; Khan, FY, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 14 (35.90) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 8 (20.51) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CH | 1 |
| Hsu, YJ | 1 |
| Chen, YC | 1 |
| Cheng, SS | 1 |
| Kuo, KC | 1 |
| Chiu, CH | 1 |
| Kuehn, R | 3 |
| Stoesser, N | 3 |
| Eyre, D | 3 |
| Darton, TC | 3 |
| Basnyat, B | 3 |
| Parry, CM | 4 |
| Jin, C | 1 |
| Gibani, MM | 1 |
| Pennington, SH | 1 |
| Liu, X | 1 |
| Ardrey, A | 1 |
| Aljayyoussi, G | 1 |
| Moore, M | 1 |
| Angus, B | 2 |
| Biagini, GA | 1 |
| Feasey, NA | 1 |
| Pollard, AJ | 3 |
| Dilhari, A | 1 |
| Pathirage, S | 1 |
| Gunasekara, C | 1 |
| Fernando, N | 1 |
| Weerasekara, D | 1 |
| McBain, A | 1 |
| Weerasekera, M | 1 |
| Park, HR | 1 |
| Kim, DM | 1 |
| Yun, NR | 1 |
| Kim, CM | 1 |
| Britto, CD | 1 |
| John, J | 2 |
| Verghese, VP | 1 |
| Hassing, RJ | 2 |
| Goessens, WH | 2 |
| Mevius, DJ | 1 |
| van Pelt, W | 2 |
| Mouton, JW | 1 |
| Verbon, A | 1 |
| van Genderen, PJ | 2 |
| McCullagh, D | 1 |
| Dobinson, HC | 1 |
| Darton, T | 1 |
| Campbell, D | 1 |
| Jones, C | 1 |
| Snape, M | 1 |
| Stevens, Z | 1 |
| Plested, E | 1 |
| Voysey, M | 1 |
| Kerridge, S | 1 |
| Martin, LB | 1 |
| Gupta, V | 1 |
| Kaur, J | 1 |
| Sobczyk-Krupiarz, I | 1 |
| Garlicki, A | 1 |
| Biesiada, G | 1 |
| Czepiel, J | 1 |
| Skwara, P | 1 |
| Salamon, D | 1 |
| Mach, T | 1 |
| Bormann, AM | 1 |
| Boulware, DR | 1 |
| Menezes, GA | 1 |
| Petit, PL | 1 |
| Bhattacharya, SS | 1 |
| Das, U | 1 |
| Choudhury, BK | 1 |
| Fernando, S | 1 |
| Molland, JG | 1 |
| Gottlieb, T | 1 |
| Harish, BN | 1 |
| Madhulika, U | 1 |
| Parija, SC | 1 |
| Slinger, R | 1 |
| Desjardins, M | 1 |
| McCarthy, AE | 1 |
| Ramotar, K | 1 |
| Jessamine, P | 1 |
| Guibord, C | 1 |
| Toye, B | 1 |
| Adachi, T | 1 |
| Sagara, H | 1 |
| Hirose, K | 2 |
| Watanabe, H | 2 |
| Krogh, K | 1 |
| Hermansen, NO | 1 |
| Wathne, KO | 1 |
| Khan, FY | 1 |
| Kamha, AA | 1 |
| Alomary, IY | 1 |
| Morita, M | 1 |
| Ito, K | 1 |
| Takahashi, H | 1 |
| Shimuta, K | 1 |
| Terajima, J | 1 |
| Ohnishi, M | 1 |
| Harada, M | 1 |
| Matsuzaki, M | 1 |
| Izumiya, H | 1 |
| Gaind, R | 1 |
| Paglietti, B | 1 |
| Murgia, M | 1 |
| Dawar, R | 1 |
| Uzzau, S | 1 |
| Cappuccinelli, P | 1 |
| Deb, M | 1 |
| Aggarwal, P | 1 |
| Rubino, S | 1 |
| Dimitrov, T | 1 |
| Udo, EE | 1 |
| Albaksami, O | 1 |
| Kilani, AA | 1 |
| Shehab, EMR | 1 |
| Threlfall, EJ | 1 |
| de Pinna, E | 1 |
| Day, M | 1 |
| Lawrence, J | 1 |
| Jones, J | 1 |
| Alam, MN | 1 |
| Haq, SA | 1 |
| Das, KK | 1 |
| Baral, PK | 1 |
| Mazid, MN | 1 |
| Siddique, RU | 1 |
| Rahman, KM | 1 |
| Hasan, Z | 1 |
| Khan, MA | 1 |
| Dutta, P | 1 |
| Leung, M | 1 |
| Leung, D | 1 |
| Venkatesan, P | 1 |
| Boswell, T | 1 |
| Innes, JA | 1 |
| Wood, MJ | 1 |
| Brown, NM | 1 |
| Millar, MR | 1 |
| Frost, JA | 1 |
| Rowe, B | 1 |
| Müller, HE | 1 |
| Mathai, D | 1 |
| Kudva, GC | 1 |
| Keystone, JS | 1 |
| Kozarsky, PE | 1 |
| Jesudason, MV | 1 |
| Lalitha, MK | 1 |
| Kaur, A | 1 |
| Thomas, M | 1 |
| Pulimood, BM | 1 |
| Nelwan, RH | 1 |
| Zulkarnain, I | 1 |
| Gunawan, J | 1 |
| Supandiman, I | 1 |
| Yusuf, H | 1 |
| Soedjana, P | 1 |
| Syahroni, A | 1 |
| Eltringham, IJ | 1 |
| Thalange, N | 1 |
| Irish, D | 1 |
| Issler, H | 1 |
| Teall, A | 1 |
| Ireland, D | 1 |
| Agalar, C | 1 |
| Usubütün, S | 1 |
| Tütüncü, E | 1 |
| Türkyilmaz, R | 1 |
| Bhutta, ZA | 2 |
| Thomsen, LL | 1 |
| Paerregaard, A | 1 |
| Farooqui, BJ | 1 |
| Sturm, AW | 1 |
| Neill, MA | 1 |
| Opal, SM | 1 |
| Heelan, J | 1 |
| Giusti, R | 1 |
| Cassidy, JE | 1 |
| White, R | 1 |
| Mayer, KH | 1 |
| Gohel, DR | 1 |
| Stanley, PJ | 1 |
| Flegg, PJ | 1 |
| Mandal, BK | 1 |
| Geddes, AM | 1 |
| Mandal, B | 1 |
| Flegg, P | 1 |
| Dunbar, E | 1 |
| Whale, K | 1 |
| Brennand, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIb, Observer-blind, Randomised Controlled Trial to Assess the Immunogenicity and Protective Efficacy of Vi Conjugated (Vi-TCV) and Unconjugated (Vi-PS) Polysaccharide Vaccines in Preventing Typhoid Infection Compared to a Control Vaccine (Meningo[NCT02324751] | Phase 2 | 112 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Investigating the Mechanisms and Determinants of Systemic and Mucosal Immunity to Salmonella Typhi and Salmonella Paratyphi A in naïve and Previously Exposed Individuals - A Challenge and Rechallenge Study[NCT02192008] | 125 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| Development of a Human Model of Salmonella Enterica Serovar Paratyphi A Challenge in Healthy Adult Volunteers[NCT02100397] | 80 participants (Anticipated) | Interventional | 2014-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ciprofloxacin and Paratyphoid Fever
| Article | Year |
|---|---|
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cefixime; Ceftriaxone | 2022 |
A systematic review of antimicrobial resistance of typhoidal
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; India; M | 2019 |
7 trials available for ciprofloxacin and Paratyphoid Fever
| Article | Year |
|---|---|
Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Female; Humans; Male; Middle | 2019 |
Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Female; Humans; Male; Middle | 2019 |
Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Female; Humans; Male; Middle | 2019 |
Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Female; Humans; Male; Middle | 2019 |
Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ciprofloxacin; Female; Healthy Volunteers; Humans; Male; M | 2015 |
Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Drug Administration Schedule; Drug Re | 1995 |
Short course ciprofloxacin therapy for enteric fever.
Topics: Adult; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Male; Paratyphoid Fever; Recurre | 1993 |
A comparative study of short course ciprofloxacin treatment in typhoid and paratyphoid fever.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Humans; Male; Paratyphoid | 1995 |
Comparison of two regimens for ciprofloxacin treatment of enteric infections.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Drug Administration Schedule; Female; Human | 1997 |
Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers.
Topics: Acute Disease; Adult; Carrier State; Ciprofloxacin; Convalescence; Disease Outbreaks; Double-Blind M | 1991 |
30 other studies available for ciprofloxacin and Paratyphoid Fever
| Article | Year |
|---|---|
Clinical manifestations and microbiological features between indigenous and imported enteric fever in Taiwan, 2010-2020.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Paratyphoid Fever; Retrospective Studies; Salmonella p | 2022 |
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefuroxime; Ciprofloxacin; Cloxacillin; D | 2020 |
Identifying the mechanism underlying treatment failure for Salmonella Paratyphi A infection using next-generation sequencing - a case report.
Topics: Aged; Amino Acid Substitution; Anti-Bacterial Agents; Azithromycin; Cefotaxime; Ceftriaxone; Ciprofl | 2019 |
Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Blood; Child; Ciprofloxacin; Drug Resistance, Bacter | 2013 |
A need to revise ciprofloxacin breakpoints for Salmonella in human beings.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Test | 2008 |
[A case of Salmonella paratyphi A infection in Poland].
Topics: Adult; Amoxicillin; Ceftriaxone; Ciprofloxacin; Drug Combinations; Drug Therapy, Combination; Humans | 2008 |
The trials of the returning traveler: ciprofloxacin failure in enteric fever.
Topics: Adult; Azithromycin; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; India | 2008 |
Analysis of mechanisms involved in reduced susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A isolates from travellers to Southeast Asia.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Asia, Southeastern; Blood; Ciprofloxacin; DNA Gyrase | 2011 |
Occurrence & antibiogram of Salmonella Typhi & S. Paratyphi A isolated from Rourkela, Orissa.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Community-Acquired Infections; Drug Resistance | 2011 |
Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused by Salmonella enterica serotype Paratyphi A.
Topics: Abscess; Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Breast Diseases; Ceftriax | 2012 |
Isolated high-level ciprofloxacin resistance in Salmonella enterica subsp. enterica serotype Paratyphi A.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Male; Microbial Sen | 2004 |
Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Micr | 2004 |
Fluoroquinolone-resistant Salmonella Paratyphi A.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Proteins; Carrier State; Ciprofloxacin; Dr | 2005 |
[Typhoid and paratyphoid fever in children].
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Multiple | 2005 |
Fulminant hepatic failure caused by Salmonella paratyphi A infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Ciprofloxacin; Dexamethasone; Gluc | 2006 |
Development of a real-time PCR assay for detection of gyrA mutations associated with reduced susceptibility to ciprofloxacin in Salmonella enterica serovar typhi and paratyphi A.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Humans; Mutation; Para | 2006 |
Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Ciprofloxacin; Deoxyribonucleases, Type II Site-Spec | 2006 |
Ciprofloxacin treatment failure in a case of typhoid fever caused by Salmonella enterica serotype Paratyphi A with reduced susceptibility to ciprofloxacin.
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacteria | 2007 |
Alternatives to ciprofloxacin use for enteric Fever, United kingdom.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Humans; | 2008 |
Simultaneous infection by a sensitive and a multiresistant strain of Salmonella paratyphi A.
Topics: Adult; Animals; Blastocystis Infections; Ceftriaxone; Ciprofloxacin; Drug Resistance, Microbial; Dru | 1995 |
Treatment of typhoid in pregnancy.
Topics: Adolescent; Adult; Asia, Western; Child; Ciprofloxacin; Drug Resistance, Multiple; Female; Humans; M | 1995 |
Ciprofloxacin resistance in Salmonella paratyphi A.
Topics: Adult; Ciprofloxacin; Drug Resistance, Microbial; Humans; Male; Microbial Sensitivity Tests; Paratyp | 1994 |
[The high risk of cancer as a motive for treatment of typhoid and paratyphoid carriers].
Topics: Adult; Aged; Bile Duct Neoplasms; Carrier State; Ciprofloxacin; Communicable Disease Control; Female | 1994 |
A relapse of paratyphoid fever after treatment with ciprofloxacin in a child with congenital biliary atresia.
Topics: Anti-Infective Agents; Biliary Atresia; Ciprofloxacin; Humans; Infant; Male; Osteomyelitis; Paratyph | 1997 |
Quinolone-resistant Salmonella paratyphi B meningitis in a newborn: a case report.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Brain Abscess; Cefotaxime; Cephalosporins; C | 1997 |
Treatment with ciprofloxacin in children with typhoid fever.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Dr | 1998 |
Eradication of a multiple drug resistant Salmonella paratyphi A causing meningitis with ciprofloxacin.
Topics: Ciprofloxacin; Drug Resistance, Microbial; Humans; Infant, Newborn; Male; Meningitis, Bacterial; Pak | 1992 |
Chloramphenicol versus ciprofloxacin in enteric fever.
Topics: Chloramphenicol; Ciprofloxacin; Drug Utilization; Humans; Paratyphoid Fever; Typhoid Fever | 1991 |
Open study of ciprofloxacin in enteric fever.
Topics: Administration, Oral; Adolescent; Adult; Ciprofloxacin; Feces; Female; Humans; Injections, Intraveno | 1989 |
Ciprofloxacin in enteric fever.
Topics: Adult; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Paratyphoid Fever; Salmonel | 1987 |